Press releases

Release
03.07.2019

VALBIOTIS announces positive results from the Phase IIA clinical study of VALEDIA®, now the first product proven effective in people with prediabetes

Download
Release
24.06.2019

VALBIOTIS participates in the first HealthTech Investor Days, organized by France Biotech

Download
Release
07.06.2019

VALBIOTIS to present novel data about TOTUM-63 and metabolic diseases prevention at the 2019 scientific sessions of the American Diabetes Association

Download
Release
28.05.2019

VALBIOTIS succeeds in the industrial production of VALEDIA®, a major scientific innovation for prediabetic people, in collaboration with the Pierre Fabre group

Download
Release
14.05.2019

VALBIOTIS will present the results of the international Phase IIA clinical study of VALEDIA® before 31 July 2019

Download
Release
02.04.2019

VALBIOTIS received two public subventions for a total amount of 885 000 euros

Download
Release
22.03.2019

VALBIOTIS presents its 2019 financial calendar

Download
Release
19.03.2019

VALBIOTIS strengthens its Supervisory Board with the appointment of Agnès TIXIER

Download
Release
11.03.2019

VALBIOTIS reports exclusive data on the prediabetes market: a considerable potential for VALEDIA®

Download